LENZ Therapeutics (LENZ) News Today $27.93 +0.97 (+3.60%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period LENZ Therapeutics (LENZ) Set to Announce Earnings on WednesdayLENZ Therapeutics (NASDAQ:LENZ) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports.October 31 at 9:54 AM | marketbeat.comLeerink Partners Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)October 30 at 2:50 PM | markets.businessinsider.comLENZ reports positive Chinese study data for far-sightedness drugOctober 29, 2024 | msn.comLENZ Therapeutics Reports Positive Phase 3 Results For LNZ100 In Presbyopia Trial In ChinaOctober 28, 2024 | markets.businessinsider.comWhy LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketOctober 28, 2024 | benzinga.comLENZ Therapeutics Shares Climb After Presbyopia Trial Hits EndpointsOctober 28, 2024 | marketwatch.comCORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100October 27, 2024 | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Recommendation of "Buy" by AnalystsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) has earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned aOctober 26, 2024 | marketbeat.comLenz Therapeutics announces FDA acceptance of NDA for LNZ100October 22, 2024 | markets.businessinsider.comLENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition TreatmentOctober 21, 2024 | marketwatch.comWhy LENZ Therapeutics Stock Hit A New 52-Week High TodayOctober 21, 2024 | benzinga.comFDA Accepts LENZ Therapeutics' NDA For LNZ100 To Treat PresbyopiaOctober 21, 2024 | markets.businessinsider.comLENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of PresbyopiaOctober 21, 2024 | globenewswire.comFY2028 Earnings Forecast for LENZ Issued By Leerink PartnrsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at Leerink Partnrs upped their FY2028 earnings per share estimates for shares of LENZ Therapeutics in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the coOctober 18, 2024 | marketbeat.comMarshall Wace LLP Makes New $390,000 Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Marshall Wace LLP purchased a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,554 shares of the company's stock, valued at aOctober 11, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Buy" by BrokeragesShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned a consensus recommendation of "Buy" from the seven analysts that are presently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy ratingOctober 1, 2024 | marketbeat.comLENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical ConferencesSeptember 30, 2024 | finance.yahoo.comRaymond James Initiates Coverage of LENZ Therapeutics (LENZ) with Outperform RecommendationSeptember 29, 2024 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Raymond JamesRaymond James initiated coverage on LENZ Therapeutics in a research report on Friday. They set an "outperform" rating and a $37.00 price target for the company.September 27, 2024 | marketbeat.comBank of New York Mellon Corp Buys 28,556 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)Bank of New York Mellon Corp raised its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 255.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,737 shares of the compSeptember 23, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 7.8%LENZ Therapeutics (NASDAQ:LENZ) Shares Up 7.8%September 13, 2024 | marketbeat.comLENZ Therapeutics Insiders Up US$178k On US$551.1k InvestmentSeptember 12, 2024 | finance.yahoo.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Recommendation of "Buy" from AnalystsShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have received a consensus rating of "Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price amSeptember 6, 2024 | marketbeat.comLENZ Therapeutics: Upcoming PDUFA, Strong Data, Some RisksAugust 30, 2024 | seekingalpha.comLENZ Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2024 | globenewswire.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024August 26, 2024 | investorplace.comWealth Enhancement Advisory Services LLC Takes $1.44 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Wealth Enhancement Advisory Services LLC acquired a new position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 83,103 shares of the company'sAugust 20, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q2 2024 Earnings Call TranscriptAugust 19, 2024 | insidermonkey.comVanguard Group Inc. Purchases Shares of 206,952 LENZ Therapeutics, Inc. (NASDAQ:LENZ)Vanguard Group Inc. acquired a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 206,952 shares of the company's stock, valued at approxAugust 18, 2024 | marketbeat.comLENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBuy Rating Reaffirmed for LENZ Therapeutics Amidst Strong Market Potential and Positive Product DataAugust 16, 2024 | markets.businessinsider.comHC Wainwright Equities Analysts Reduce Earnings Estimates for LENZ Therapeutics, Inc. (NASDAQ:LENZ)LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at HC Wainwright decreased their FY2028 earnings estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Thursday, August 15th. HC Wainwright analyst M. Caufield now anticipates thAugust 16, 2024 | marketbeat.comLENZ Therapeutics' (LENZ) Overweight Rating Reaffirmed at Piper SandlerPiper Sandler reaffirmed an "overweight" rating and issued a $36.00 price target on shares of LENZ Therapeutics in a report on Thursday.August 15, 2024 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on LENZ Therapeutics (LENZ)August 15, 2024 | markets.businessinsider.comBuy Rating for LENZ Therapeutics on Promising Presbyopia Treatment and Market PotentialAugust 15, 2024 | markets.businessinsider.comLENZ Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | globenewswire.comLENZ Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.50) Per Share (NASDAQ:LENZ)LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Stock analysts at HC Wainwright issued their Q2 2024 earnings estimates for LENZ Therapeutics in a research note issued on Monday, August 12th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.50)August 14, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from AnalystsShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been given a consensus recommendation of "Buy" by the six research firms that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-yeaAugust 12, 2024 | marketbeat.comLENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of PresbyopiaAugust 12, 2024 | globenewswire.comLENZ Therapeutics (NASDAQ:LENZ) Earns Buy Rating from Analysts at HC WainwrightHC Wainwright initiated coverage on LENZ Therapeutics in a research note on Monday. They issued a "buy" rating and a $38.00 target price on the stock.August 12, 2024 | marketbeat.comLENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024August 7, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Purchases Shares of 37,176 LENZ Therapeutics, Inc. (NASDAQ:LENZ)Jacobs Levy Equity Management Inc. purchased a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 37,176 shares of the company's stock, valued at apAugust 3, 2024 | marketbeat.comJennison Associates LLC Invests $3.01 Million in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Jennison Associates LLC acquired a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 134,740 shares of the companJuly 10, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Trading Up 0.7%LENZ Therapeutics (NASDAQ:LENZ) Trading Up 0.7%July 5, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Trading Down 1.4%LENZ Therapeutics (NASDAQ:LENZ) Shares Down 1.4%June 13, 2024 | marketbeat.comLENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024June 10, 2024 | globenewswire.comLENZ Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Director James W. Mccollum Purchases 31,332 SharesMay 15, 2024 | insidertrades.comInsider Buying: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Director Acquires 31,332 Shares of StockLENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) Director James W. Mccollum purchased 31,332 shares of the business's stock in a transaction on Monday, May 13th. The stock was purchased at an average cost of $15.99 per share, with a total value of $500,998.68. Following the acquisition, the director now owns 525,565 shares in the company, valued at $8,403,784.35. The purchase was disclosed in a legal filing with the SEC, which is available at this link.May 14, 2024 | marketbeat.comLENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.com Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here LENZ Media Mentions By Week LENZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼0.580.42▲Average Medical News Sentiment LENZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼82▲LENZ Articles Average Week Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KYMR News Today APGE News Today TWST News Today CGON News Today SRRK News Today SWTX News Today VCEL News Today BEAM News Today TARS News Today RXRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
